Shabana K M, Abdul Nazeer K A, Pradhan Meeta, Palakal Mathew
BMC Bioinformatics. 2015;16 Suppl 17(Suppl 17):S5. doi: 10.1186/1471-2105-16-S17-S5. Epub 2015 Dec 7.
The identification of new therapeutic uses of existing drugs, or drug repositioning, offers the possibility of faster drug development, reduced risk, lesser cost and shorter paths to approval. The advent of high throughput microarray technology has enabled comprehensive monitoring of transcriptional response associated with various disease states and drug treatments. This data can be used to characterize disease and drug effects and thereby give a measure of the association between a given drug and a disease. Several computational methods have been proposed in the literature that make use of publicly available transcriptional data to reposition drugs against diseases.
In this work, we carry out a data mining process using publicly available gene expression data sets associated with a few diseases and drugs, to identify the existing drugs that can be used to treat genes causing lung cancer and breast cancer.
Three strong candidates for repurposing have been identified- Letrozole and GDC-0941 against lung cancer, and Ribavirin against breast cancer. Letrozole and GDC-0941 are drugs currently used in breast cancer treatment and Ribavirin is used in the treatment of Hepatitis C.
确定现有药物的新治疗用途,即药物重新定位,为加快药物研发、降低风险、降低成本以及缩短审批路径提供了可能性。高通量微阵列技术的出现使得全面监测与各种疾病状态和药物治疗相关的转录反应成为可能。这些数据可用于表征疾病和药物效应,从而衡量特定药物与疾病之间的关联。文献中已经提出了几种计算方法,利用公开可用的转录数据对针对疾病的药物进行重新定位。
在这项工作中,我们使用与一些疾病和药物相关的公开可用基因表达数据集进行数据挖掘过程,以确定可用于治疗导致肺癌和乳腺癌的基因的现有药物。
已确定三种强有力的重新利用药物的候选药物——来曲唑和GDC-0941用于治疗肺癌,利巴韦林用于治疗乳腺癌。来曲唑和GDC-0941是目前用于乳腺癌治疗的药物,利巴韦林用于治疗丙型肝炎。